File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Treatment of de novo acute myeloid leukaemia in Hong Kong: A twenty-year experience (1975 to 1996)

TitleTreatment of de novo acute myeloid leukaemia in Hong Kong: A twenty-year experience (1975 to 1996)
Authors
Issue Date1999
PublisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/IMJ
Citation
Australian And New Zealand Journal Of Medicine, 1999, v. 29 n. 5, p. 726-730 How to Cite?
AbstractBackground: Small patient numbers and short follow-up are common in some acute myeloid leukaemia (AML) studies and data on secondary malignancies after treatment of AML are rare. Aims: To determine the prognostic factors and long-term treatment results. Methods: A retrospective study of patients with de novo AML under the age of 60 over a 20-year period in which two induction therapy regimens: 7:3 (1975-1983) and 7:3:7 (1984-1996) and three consolidation chemotherapy regimens: 5:2 (1975-1983), 5:2:5 (1984-1990) and Ara-C/mitoxantrone (1991-1996) were used. Disease-free (DFS), overall survivals (OS) and prognostic factors were analysed. Results: Two-hundred and two of 276 (73%) patients attained complete remission (CR). The CR rates of 7:3 and 7:3:7 regimens were 70.5% and 74.5% respectively (p=0.92). The median DFS was 12 months and the projected DFS at 10- and 20-years were 23% and 21% respectively. For patients consolidated with 5:2, 5:2:5 and Ara- C/mitoxantrone, the median DFS was 15 m, 12 m and 11 m respectively and the projected ten-year DFS were 27%, 21% and 18% respectively (p=0.2). Ninety per cent of relapses occurred within two years from remission but there were two late relapses at 109 m and 120 m respectively. Young age and FAB M3 subtype were favourable prognostic factors to OS (p=0.04) and DFS (p=0.006) respectively. There was no secondary solid tumour in the long-term survivors. Conclusion: Our experience confirmed the efficacy of standard-dose Ara- C/daunorubicin and the prognostic value of age and FAB subtype. Median and projected DFS were similar to western studies.
Persistent Identifierhttp://hdl.handle.net/10722/162274
ISSN
2002 Impact Factor: 0.524
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChim, CSen_US
dc.contributor.authorLiang, Ren_US
dc.contributor.authorKwong, YLen_US
dc.contributor.authorLie, AKWen_US
dc.contributor.authorTodd, Den_US
dc.contributor.authorChan, TKen_US
dc.date.accessioned2012-09-05T05:18:35Z-
dc.date.available2012-09-05T05:18:35Z-
dc.date.issued1999en_US
dc.identifier.citationAustralian And New Zealand Journal Of Medicine, 1999, v. 29 n. 5, p. 726-730en_US
dc.identifier.issn0004-8291en_US
dc.identifier.urihttp://hdl.handle.net/10722/162274-
dc.description.abstractBackground: Small patient numbers and short follow-up are common in some acute myeloid leukaemia (AML) studies and data on secondary malignancies after treatment of AML are rare. Aims: To determine the prognostic factors and long-term treatment results. Methods: A retrospective study of patients with de novo AML under the age of 60 over a 20-year period in which two induction therapy regimens: 7:3 (1975-1983) and 7:3:7 (1984-1996) and three consolidation chemotherapy regimens: 5:2 (1975-1983), 5:2:5 (1984-1990) and Ara-C/mitoxantrone (1991-1996) were used. Disease-free (DFS), overall survivals (OS) and prognostic factors were analysed. Results: Two-hundred and two of 276 (73%) patients attained complete remission (CR). The CR rates of 7:3 and 7:3:7 regimens were 70.5% and 74.5% respectively (p=0.92). The median DFS was 12 months and the projected DFS at 10- and 20-years were 23% and 21% respectively. For patients consolidated with 5:2, 5:2:5 and Ara- C/mitoxantrone, the median DFS was 15 m, 12 m and 11 m respectively and the projected ten-year DFS were 27%, 21% and 18% respectively (p=0.2). Ninety per cent of relapses occurred within two years from remission but there were two late relapses at 109 m and 120 m respectively. Young age and FAB M3 subtype were favourable prognostic factors to OS (p=0.04) and DFS (p=0.006) respectively. There was no secondary solid tumour in the long-term survivors. Conclusion: Our experience confirmed the efficacy of standard-dose Ara- C/daunorubicin and the prognostic value of age and FAB subtype. Median and projected DFS were similar to western studies.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/IMJen_US
dc.relation.ispartofAustralian and New Zealand Journal of Medicineen_US
dc.subject.meshAcute Diseaseen_US
dc.subject.meshAdulten_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Therapeutic Useen_US
dc.subject.meshDisease-Free Survivalen_US
dc.subject.meshFemaleen_US
dc.subject.meshHong Kong - Epidemiologyen_US
dc.subject.meshHumansen_US
dc.subject.meshLeukemia, Myeloid - Drug Therapy - Mortalityen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPrognosisen_US
dc.subject.meshRetrospective Studiesen_US
dc.titleTreatment of de novo acute myeloid leukaemia in Hong Kong: A twenty-year experience (1975 to 1996)en_US
dc.typeArticleen_US
dc.identifier.emailChim, CS:jcschim@hku.hken_US
dc.identifier.emailLiang, R:rliang@hku.hken_US
dc.identifier.emailKwong, YL:ylkwong@hku.hken_US
dc.identifier.authorityChim, CS=rp00408en_US
dc.identifier.authorityLiang, R=rp00345en_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1445-5994.1999.tb01622.x-
dc.identifier.pmid10630655-
dc.identifier.scopuseid_2-s2.0-0032705963en_US
dc.identifier.hkuros49591-
dc.identifier.hkuros49642-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0032705963&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume29en_US
dc.identifier.issue5en_US
dc.identifier.spage726en_US
dc.identifier.epage730en_US
dc.identifier.isiWOS:000083654900013-
dc.publisher.placeAustraliaen_US
dc.identifier.scopusauthoridChim, CS=7004597253en_US
dc.identifier.scopusauthoridLiang, R=26643224900en_US
dc.identifier.scopusauthoridKwong, YL=7102818954en_US
dc.identifier.scopusauthoridLie, AKW=24284842400en_US
dc.identifier.scopusauthoridTodd, D=7201388182en_US
dc.identifier.scopusauthoridChan, TK=7402687762en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats